share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024財年三季報
美股SEC公告 ·  2024/11/14 07:06

Moomoo AI 已提取核心訊息

ZyVersa Therapeutics reported a net loss of $2.4 million for Q3 2024, compared to $2.9 million in Q3 2023. Research and development expenses decreased 35.3% to $0.4 million, while general and administrative expenses declined 17.7% to $1.8 million. The company ended the quarter with $0.1 million in cash.The company's operating expenses totaled $2.3 million for Q3 2024, down from $2.9 million in the prior year period. The decrease was primarily driven by reduced manufacturing and pre-clinical costs for IC 100 and VAR 200 programs, along with lower professional fees and insurance costs. Interest expense increased to $0.1 million due to vendor charges on outstanding amounts.Management expressed substantial doubt about the company's ability to continue as a going concern, citing limited cash reserves only sufficient for month-to-month operations. Subsequent to quarter end, ZyVersa raised $3.1 million through warrant exercises and its at-the-market facility. The company continues to evaluate additional financing opportunities to fund its clinical development programs.
ZyVersa Therapeutics reported a net loss of $2.4 million for Q3 2024, compared to $2.9 million in Q3 2023. Research and development expenses decreased 35.3% to $0.4 million, while general and administrative expenses declined 17.7% to $1.8 million. The company ended the quarter with $0.1 million in cash.The company's operating expenses totaled $2.3 million for Q3 2024, down from $2.9 million in the prior year period. The decrease was primarily driven by reduced manufacturing and pre-clinical costs for IC 100 and VAR 200 programs, along with lower professional fees and insurance costs. Interest expense increased to $0.1 million due to vendor charges on outstanding amounts.Management expressed substantial doubt about the company's ability to continue as a going concern, citing limited cash reserves only sufficient for month-to-month operations. Subsequent to quarter end, ZyVersa raised $3.1 million through warrant exercises and its at-the-market facility. The company continues to evaluate additional financing opportunities to fund its clinical development programs.
ZyVersa Therapeutics在2024年第三季度報告淨虧損240萬美元，而2023年第三季度爲290萬美元。研發費用下降了35.3%，至40萬美元，而一般和行政費用下降了17.7%，至180萬美元。公司在本季度結束時現金爲10萬美元。公司的營業費用在2024年第三季度總計230萬美元，低於上一年同期的290萬美元。下降主要是由於IC 100和VAR 200項目的製造和臨牀前成本減少，以及專業費用和保險費用的降低。由於供應商對未支付金額的收費，利息費用增加至10萬美元。管理層對公司能否持續經營表示出明顯的懷疑，指出現金儲備有限，僅足以支持月度運營。在季度結束後，ZyVersa通過認股權證行使和市場融資方式融資310萬美元。公司繼續評估其他融資機會，以資助其臨牀開發項目。
ZyVersa Therapeutics在2024年第三季度報告淨虧損240萬美元，而2023年第三季度爲290萬美元。研發費用下降了35.3%，至40萬美元，而一般和行政費用下降了17.7%，至180萬美元。公司在本季度結束時現金爲10萬美元。公司的營業費用在2024年第三季度總計230萬美元，低於上一年同期的290萬美元。下降主要是由於IC 100和VAR 200項目的製造和臨牀前成本減少，以及專業費用和保險費用的降低。由於供應商對未支付金額的收費，利息費用增加至10萬美元。管理層對公司能否持續經營表示出明顯的懷疑，指出現金儲備有限，僅足以支持月度運營。在季度結束後，ZyVersa通過認股權證行使和市場融資方式融資310萬美元。公司繼續評估其他融資機會，以資助其臨牀開發項目。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Dogwood Therapeutics
    DWTX
    -- 2.650
    Camp4 Therapeutics
    CAMP
    -- 6.020
    Channel Therapeutics
    CHRO
    -- 2.400
    Allakos
    ALLK
    -- 1.065
    Exicure
    XCUR
    -- 12.3700
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啓，全球股市新風口在哪裏？
    ▪️加密貨幣政策能否利好crypto? ▪️關稅政策能否利好中概等海外資產？ ▪️在特朗普政策下，有哪些投資機會值得關注？ 展开
    離川普上臺只有7天了～